Outcomes of invasive stereotactic thalamotomy using dentatorubrothalamic tractography targeting for patients with drug refractory tremor
Objective: The purpose of this study was to determine whether tremor reduces in patients after stereotactic thalamotomy using tractography targeting the dentatorubrothalamic (DRT) tract. Background:…MS-Related Tremor in a Patient with Multiple Sclerosis Treated with Thermal Ablation of the Left Ventral Intermediate (VIM) Thalamic Nucleus: The Role of Tractography-Guided Targeting
Objective: To present a case of kinetic-postural tremor secondary to multiple sclerosis (MS) successfully treated with tractography-guided thermal ablation of the left dentatorubrothalamic tract (DRT)…Subthalamotomy and thalamotomy using MgFUS: Retrospective review of 9 years of treating Parkinson’s disease and Essential Tremor.
Objective: To report a 9-year single-center experience using MRgFUS thermoablation for movement disorders. Background: Over 22000 patients with Essential Tremor (ET), Parkinson´s disease (PD) and…Blinded video-based analysis of dystonia before and after unilateral High Intensity Focused Ultrasound thalamotomy in Essential and Dystonic Tremor
Objective: To determine the risk of worsening or unmasking dystonia following a unilateral High Intensity Focused Ultrasound ventral intermediate thalamotomy (Vim-HiFUS) in medication refractory Essential…A Systematic Review of Motor Improvement Caused by Deep Brain Stimulation in Post-Stroke Movement Disorder Patients
Objective: Evaluate the effect of DBS on motor improvement in PSMD. Background: Post-stroke movement disorders (PSMD) impair motor function and quality of life. Traditional rehabilitation…Variant Ataxia Telangiectasia: A Novel ATM Gene Mutation With Disabling Tremor and Response to Deep Brain Stimulation
Objective: We describe a patient with a novel ATM gene variant presenting with tremor, neuropathy, and late-onset ataxia. Background: Ataxia Telangiectasia (AT) is an autosomal…Suvecaltamide Metabolites Are CaV3 Modulators and Contribute to Pharmacological Effect
Objective: To determine the potency-concentration relationships and combined pharmacological effects for suvecaltamide and its 2 active metabolites (JZZ05000034=M01, JZZ05000035=M02; total active moiety [TAM]). Background: T-type…SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor
Objective: KINETIC2 is a multicenter, randomized, placebo-controlled, dose-response Ph2b study evaluating SAGE-324/BIIB124 for treatment of essential tremor (ET). Background: ET is a common movement disorder1,2…Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor
Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 17
- Next Page »